DEV

You are viewing our development site. Please share feedback with support@dosevault.ai or on our Discord server. See what is new in the changelog.

ARA-290 (Cibinetide)

ARA-290 (cibinetide) is a short peptide modeled on the helix-B domain of erythropoietin. It selectively activates the innate repair receptor (a heteromer of the EPO receptor and the beta-common receptor) that mediates erythropoietin's tissue-protective, anti-inflammatory, and healing effects, without engaging the homodimeric EPO receptor that drives red-blood-cell production. This separation is why it can promote nerve repair and reduce neuropathic pain without raising hematocrit.

Molecular Profile
linear
11 AA Sequence
Evidence grade (Limited): Mostly preclinical or low-quality human studies. This grade reflects the overall quality of available research on this compound and does not constitute a clinical recommendation.
CAS
1208243-50-8
Formula
helix-B 11-mer (non-erythropoietic EPO derivative)
Chain length
11 aa
Sequence
pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (helix-B 11-mer)
Onset and duration

No acute perceptible effect; reported benefits build over days to weeks of consistent use.

Storage and reconstitution

Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.

Clinical Evidence

What the literature says

Scientific Overview

According to PubMed, a randomized double-blind pilot in 22 sarcoidosis patients with small-fiber neuropathy found IV ARA-290 (2 mg, three times weekly for 4 weeks) significantly improved neuropathy symptom scores versus placebo with no safety concerns (Heij L et al., Mol Med 2012). A 2014 review of two Phase 2 trials reported consistent symptom improvement plus increased corneal nerve fibers without stimulating erythropoiesis (van Velzen M et al., Expert Opin Investig Drugs 2014). It is investigational and not approved.

Pharmacokinetics

Routes
SubcutaneousIntravenous

Last reviewed: 2026-06-15

Research Guide

How users approach this compound

The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.

Typical Dose Range Observed

1–8 mg
subcutaneous, daily (research dosing)

Research Protocols

Common Dosages

Sarcoidosis SFN (Phase 2)

2 mg IV or 1-8 mg SC
Three times weekly to daily (per trial)

Investigational; not an approved regimen

Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Reported Uses

  • Small-fiber neuropathy in sarcoidosis (Phase 2)
  • Investigational use in diabetic and other neuropathies
  • Research interest in tissue protection and anti-inflammatory healing

Key Research Benefits

  • Activates the innate repair receptor to promote tissue protection and healing
  • Reduced neuropathic pain symptoms in sarcoidosis small-fiber neuropathy trials
  • Increased corneal nerve fiber measures (a marker of small-nerve regeneration) without raising hematocrit

Potential Side Effects

Generally well tolerated in trials
Injection-site reactions
Long-term safety not established

Considerations and Cautions

  • No approved indication; not for use outside research
  • Hypersensitivity to the peptide
  • Long-term safety not established

Labs to monitor

Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.

Dose Calculator

Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

10 Units

or 0.10 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Stack ARA-290 (Cibinetide)with…

Curated stacking partners researched alongside ARA-290 (Cibinetide). Each link opens a dedicated stack page with combined benefits, side-effect overlap, and half-life considerations.

ARA-290 (Cibinetide) by goal

Read ARA-290 (Cibinetide)'s profile filtered through specific research goals.

Related Tools

Not medical advice

Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.